Production (Stage)
BioLife Solutions, Inc.
BLFS
$21.78
-$0.32-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.98% | -2.57% | -43.61% | -55.24% | -57.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.98% | -2.57% | -43.61% | -55.24% | -57.92% |
| Cost of Revenue | 15.56% | -25.78% | -74.89% | -82.16% | -78.75% |
| Gross Profit | 25.02% | 12.56% | 2.21% | -9.27% | -21.49% |
| SG&A Expenses | -4.51% | -14.49% | -30.66% | -31.01% | -26.46% |
| Depreciation & Amortization | -9.53% | -28.66% | -66.17% | -66.24% | -66.19% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.93% | -21.00% | -53.60% | -58.04% | -54.91% |
| Operating Income | 80.08% | 75.57% | 86.69% | 68.39% | 42.06% |
| Income Before Tax | 40.36% | 43.07% | 99.12% | 80.29% | 91.04% |
| Income Tax Expenses | -46.46% | -491.67% | -296.77% | 82.88% | 97.71% |
| Earnings from Continuing Operations | 41.02% | 43.76% | 99.43% | 80.27% | 90.84% |
| Earnings from Discontinued Operations | 94.60% | 80.20% | -104.97% | -525.14% | -933.13% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.86% | 70.32% | 53.44% | 10.06% | 55.85% |
| EBIT | 80.08% | 75.57% | 86.69% | 68.39% | 42.06% |
| EBITDA | 132.10% | 114.94% | 116.67% | 91.76% | 52.10% |
| EPS Basic | 84.29% | 71.38% | 55.89% | 13.74% | 57.33% |
| Normalized Basic EPS | 83.36% | 76.34% | 87.01% | 68.48% | 43.03% |
| EPS Diluted | 83.58% | 70.72% | 55.89% | 13.74% | 57.33% |
| Normalized Diluted EPS | 83.16% | 76.18% | 87.01% | 68.48% | 43.03% |
| Average Basic Shares Outstanding | 4.91% | 5.37% | 5.56% | 4.61% | 3.71% |
| Average Diluted Shares Outstanding | 5.69% | 6.16% | 5.56% | 4.61% | 3.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |